Stifel raised the firm’s price target on OptimizeRx (OPRX) to $12.50 from $8 and keeps a Buy rating on the shares. Revenue exceeded consensus and the company raised 2025 revenue guidance to 10%-15% growth up from at least 8.5%, notes the analyst following what the firm calls “another solid quarter.” While there is “still work to be done,” the firm remains “encouraged” by company’s progress and new CEO’s plan to drive higher-margin subscription revenue over time, the analyst added.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target raised to $14 from $11 at Citizens JMP
- OptimizeRx Reports Strong Q1 2025 Financial Growth
- OptimizeRx: Strong Financial Performance and Strategic Growth Positioning for Potential Acquisition
- OptimizeRx reports Q1 non-GAAP EPS 8c, consensus (12c)
- OptimizeRx sees FY25 revenue $101M-$106M, consensus $101.26M